Mainz Biomed, Bantleon partner, initiate second phase of CRC screening program

Mainz Biomed announced the second phase of its colorectal cancer, CRC, screening campaign through its BGM partnership with Bantleon, a shareholder of German AVIA and renowned for its high-performance lubricants and service solutions. Bantleon selected ColoAlert, Mainz Biomed’s highly efficacious and easy-to-use screening test for CRC, for its corporate health program, BGM. This continued BGM initiative follows a successful pilot program and will launch in Q1 2024 in line with CRC awareness month March. Darin Leigh, Chief Commercial Officer at Mainz Biomed, added: “Early detection is key to increasing treatment options as well as survival rates for colorectal cancer patients. Screening at regular intervals is essential to detecting the disease in early stages where it can be successfully treated and dramatically improve patient outcomes. We applaud Bantleon for their highly progressive approach to the wellbeing of their employees and look forward to our continued collaboration as we work to spare more people from the devastating impacts of this disease.”